Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
← catalyst calendarSponsored by Boundless Bio, Inc. (industry) · BOLD — their whole pipeline →.
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-24 | actual | When the study began enrolling |
| Primary completion | 2026-03-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-17 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Triple Negative Breast Cancer (TNBC)
- High Grade Serous Ovarian Carcinoma
- High Grade Endometrial Carcinoma
- Anogenital Cancer
- Head and Neck (HNSCC)
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Cervical Squamous Cell Carcinoma
- ER+ Breast Cancer
- Leiomyosarcoma (LMS)
- Undifferentiated Pleomorphic Sarcoma (UPS)
- Pancreatic Cancer Metastatic
- Small Cell Lung Cancer
Interventions
- Drug: BBI-355
- Drug: Erlotinib
- Drug: Futibatinib
- Drug: BBI-825
Primary outcomes
what the primary-completion date above is the date OFPublications
- PMID 36378548 — cited as background
- PMID 29788155 — cited as background
- PMID 39506153 — cited as background
- PMID 34752712 — cited as background
- PMID 28178237 — cited as background
- PMID 36123406 — cited as background
- PMID 32807987 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BOLD's whole pipeline · Catalyst calendar · Every registered study · What changed